H

Hugel Inc
KOSDAQ:145020

Watchlist Manager
Hugel Inc
KOSDAQ:145020
Watchlist
Price: 335 000 KRW Market Closed
Market Cap: 4.2T KRW

EV/EBIT
Enterprise Value to EBIT

23.1
Current
12.7
Median
3.8
Industry
Higher than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
23.1
=
Enterprise Value
3.8T KRW
/
EBIT
166.2B KRW
Market Cap EV/EBIT
KR
Hugel Inc
KOSDAQ:145020
4.2T KRW 23.1
FR
Pharnext SCA
OTC:PNEXF
6T USD -209 002.7
US
Abbvie Inc
NYSE:ABBV
369B USD 25.7
US
Amgen Inc
NASDAQ:AMGN
167.8B USD 29.3
US
Gilead Sciences Inc
NASDAQ:GILD
139.4B USD 14.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.1B USD 26.5
US
Epizyme Inc
F:EPE
94.1B EUR -520.2
AU
CSL Ltd
ASX:CSL
120.7B AUD 21.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
69.4B USD 11.3
US
Seagen Inc
F:SGT
39.3B EUR -55.1
NL
argenx SE
XBRU:ARGX
32.1B EUR -2 258.6
EBIT Growth EV/EBIT to Growth
KR
H
Hugel Inc
KOSDAQ:145020
Average EV/EBIT: 21.6
23.1
27%
0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -209 002.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25.7
28%
0.9
US
Amgen Inc
NASDAQ:AMGN
29.3
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.3
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.5
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -520.2 N/A N/A
AU
CSL Ltd
ASX:CSL
21.3
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.3
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.1 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 258.6 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
17.4
2-Years Forward
EV/EBIT
13.8
3-Years Forward
EV/EBIT
11.2